COCheryl Oncken

Cheryl Oncken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cheryl Oncken has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Henry R. Kranzler

    Department of Psychiatry, University of Pennsylvania Perelman School of Medicine and Philadelphia VAMC, Philadelphia, PA

    4 shared publications
  • Richard Feinn

    Department of Medical Sciences, Frank H. Netter MD School of Medicine, Quinnipiac University, Hamden, CT

    4 shared publications
  • Henry Kranzler

    University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA

    3 shared publications
  • Jonathan Covault

    Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT

    3 shared publications
  • Winston Campbell

    Department of Obstetrics and Gynecology

    3 shared publications
  • Alicia Marie Allen

    National Center for Opioid and Addiction Research, Arkansas Children's Research Institute, 13 Children's Way, Slot 842, Little Rock, AR 72202, United States

    2 shared publications

Latest Publications

  • Genetic Vulnerability to Menthol Cigarette Preference in Women

    by Cheryl Oncken, Richard Feinn, Jonathan Covault, Valerie Duffy, Ellen Dornelas, Henry R. Kranzler, Heather Z. Sankey

    Background: Smokers may prefer menthol cigarettes to mask the bitter taste of nicotine. Variation in the taste receptor gene, TAS2R38, may contribute to preference for menthol cigarettes. Aims: To determine whether two common haplotypes of TAS2R38 (proline-alanine-valine [PAV] and alanine-valine-isoleucine [AVI]), which have been associated, respectively, with bitter taste or a lack of bitter taste produced by propylthiouracil, are associated with preference for menthol cigarettes. Methods: Data on smoking and blood for DNA extraction and genotyping were obtained from 323 pregnant non-Hispanic or Hispanic Caucasian smokers. We genotyped three TAS2R38 single nucleotide polymorphisms (rs713598, rs1726866, and rs10246939) and constructed haplotypes. We examined associations between menthol preference and the frequency and distribution of the AVI and PAV haplotypes among study participants. Results: Participants smoked an average of 16 cigarettes per day before pregnancy. The PAV and AVI haplotype frequencies were 48% and 45%, respectively. Non-Hispanic women were less likely than Hispanic women to smoke menthol cigarettes. As hypothesized, the frequency of the PAV haplotype was greater in menthol than non-menthol smokers in both non-Hispanics (54% vs. 30%; χ2 = 13.04, P < .001) and Hispanics (53% vs. 25%; χ2 = 5.77, P = .016). This effect persisted after controlling for potential confounders in multivariate logistic regression. Menthol smokers had a greater number of PAV haplotypes/individual than non-menthol smokers [non-Hispanics odds ratio (OR) = 3.02 (1.56–5.85); P = .001; Hispanics OR = 3.60 (1.23–10.56); P = .020]. Conclusions: These preliminary data support the hypothesis that a genetic propensity to experience heightened bitter taste perception increases the preference for menthol cigarettes.


  • Nicotine Concentrations With Electronic Cigarette Use: Effects of Sex and Flavor

    by Cheryl A. Oncken, Mark D. Litt, Lynn D. McLaughlin, Nausherwan A. Burki

    This study examined overall changes in nicotine concentrations when using a popular e-cigarette and 18mg/mL nicotine e-Juice, and it further explored effects of sex and flavorings on these concentrations. We recruited nontreatment-seeking smokers who were willing to try e-cigarettes for 2 weeks and abstain from cigarette smoking. Subjects were randomized to either menthol tobacco or non-menthol tobacco-flavored e-cigarette use for 7–10 days, and the next week they were crossed over to the other condition. On the last day of e-cigarette use of each flavor, subjects completed a laboratory session in which they used the e-cigarette for 5min ad libitum. Nicotine concentrations were obtained 5min before and 5, 10, 15, 20, and 30min after the onset of e-cigarette use. Twenty subjects completed at least 1 monitoring session. Nicotine concentrations significantly increased from baseline to 5min by 4ng/mL at the first laboratory session (p < .01) and by 5.1ng/mL at the second laboratory session (p < .01). Combining sessions, there were no main effects of sex or preferred flavor (based on smoking history) on changes in nicotine concentrations. After adding preferred flavor, sex, and visit order to the model, there was a significant preferred flavor by sex interaction (p < .01), such that women who received nonpreferred flavors had lower nicotine concentrations and rated their e-cigarette as less likeable (p < .01). We found nicotine concentrations significantly increase after e-cigarette use for 5min, and flavor may impact nicotine concentrations with e-cigarette use in women.


  • Effects of alcohol intake on balance and stability in older adults: A pilot study

    by Yinghui Duan, Lisa Barry, Jonathan Covault, Anne Kenny, Cheryl Oncken, Richard Bohannon, James Grady, Helen Wu

  • Open Access

    Women and Smoking: The Effect of Gender on the Epidemiology, Health Effects, and Cessation of Smoking

    by Alicia M. Allen, Cheryl Oncken, Dorothy Hatsukami

    Smoking is still the leading cause of premature morbidity and mortality. This paper examines new research on gender differences and the epidemiology of smoking, smoking-related morbidity and mortality, and factors that affect smoking cessation. The rate of decline in the prevalence of smoking has been slowing, especially among adolescent girls. New research suggests that, compared with men, women may be more susceptible to smoking-related morbidity and mortality. Gender-related barriers to smoking cessation include weight gain, sex hormones, and mood. Furthermore, the sensory aspects of smoking may have more of an effect on smoking treatment for women than for men. We discuss new studies that examine smoking-cessation interventions that may be particularly beneficial for women, including exercise (as an adjunct intervention), very low nicotine content cigarettes, and a variety of pharmacotherapy. Further research is needed to identify and target the gender-specific needs of smokers.


  • Effect of nicotine patch on energy intake and weight gain in postmenopausal women during smoking cessation

    by Alicia M. Allen, Alison Kleppinger, Harry Lando, Cheryl Oncken


  • Topiramate for Smoking Cessation: A Randomized, Placebo-Controlled Pilot Study

    by Cheryl Oncken, Albert J. Arias, Richard Feinn, Mark Litt, Jonathan Covault, Mehmet Sofuoglu, Henry R. Kranzler

    Topiramate (TOP) blocks glutamate receptors and facilitates GABA (γ-aminobutyric acid) neurotransmission, effects that may facilitate smoking cessation. We compared the effects of behavioral counseling combined with (a) TOP, (b) TOP/nicotine patch (TOP/NIC), or (c) placebo (PLC) for smoking cessation. We conducted a 10-week randomized trial in which subjects and research personnel were blinded to TOP versus PLC but not to the TOP/NIC patch condition. In groups receiving TOP, the medication dosage was titrated gradually up to 200mg/day. The smoking quit date (QD) was scheduled after 2 weeks of medication treatment. NIC (21mg) was started on the QD in subjects randomized to the TOP/NIC condition. The main outcome measure was the end-of-treatment, 4-week continuous abstinence rate (CAR; biochemically confirmed). Fifty-seven subjects were randomized to treatment. The 4-week CAR was 1 of 19 (5%) in the PLC group, 5 of 19 (26%) in the TOP group, and 7 of 19 (37%) in the TOP/NIC group (p = .056). Pairwise comparisons showed a difference between TOP/NIC and PLC (p = .042) and a nonsignificant difference between TOP and PLC (p = .18). The PLC group gained 0.37 lb/week, the TOP group lost 0.41 lb/week, and the TOP/NIC group lost 0.07 lb/week (p = .004). Pairwise comparisons showed a difference between TOP and PLC (p < .001) and between TOP/NIC and PLC groups (p = .035). Paresthesia was more frequent in subjects on TOP than PLC (p = .011). TOP, alone or in combination with the NIC, resulted in a numerically higher quit rate than PLC and decreased weight. A larger, PLC-controlled trial is needed to confirm these findings.


  • Open Access

    Prenatal tobacco prevention and cessation interventions for women in low‐ and middle‐income countries

    by Cheryl A. Oncken, Patricia M. Dietz, VAN T. Tong, José M. Belizán, Jorge E. Tolosa, Vincenzo Berghella, Robert L. Goldenberg, Harry A. Lando, Jonathan M. Samet, Michele H. Bloch

    Although the prevalence of tobacco use is decreasing in many high‐income countries, it is increasing in many low‐ and middle‐income countries. The health and economic burden of increasing tobacco use and dependence is predictable and will have devastating effects in countries with limited resources, particularly for vulnerable populations such as pregnant women. We sought to review effective tobacco prevention and intervention strategies for decreasing tobacco use and secondhand smoke exposure before and during pregnancy in high‐, middle‐, and low‐income countries. We reviewed several types of interventions, including population‐level efforts (increasing tobacco prices, implementing tobacco control policies), community interventions, clinical interventions, and pharmacological treatments.A second purpose of this report is to present findings of an international expert working group that was convened to review the evidence and to establish research priorities in the following areas: (a) preventing the uptake and reducing tobacco use among girls and women of reproductive age; and (b) reducing tobacco use and secondhand smoke exposure among pregnant women. The working group considered the evidence on existing interventions in terms of burden of disease, intervention impact, intervention costs, feasibility of integration into existing services, uniqueness of the contribution, and overall feasibility. Finally, we present the working group's recommendations for intervention research priorities.


  • Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers

    by Cheryl Oncken, Winston Campbell, Grace Chan, Dorothy Hatsukami, Henry R. Kranzler

    Objective. To examine the short-term effects of the nicotine patch or nasal spray on measures of nicotine exposure, withdrawal symptoms, and on maternal and fetal heart rates in pregnant smokers. Methods. We measured nicotine/cotinine concentrations and maternal and fetal heart rates during an 8-h monitoring session while smoking and again after 4 days of nicotine patch (15 mg/16 h), nasal spray (recommended regimen of 24 doses per day), or placebo treatment. Nicotine withdrawal symptoms were assessed daily. Results. Twenty-one subjects, who smoked an average of 17 cigarettes per day, completed both monitoring sessions. Nicotine concentrations decreased from baseline smoking concentrations in all groups (p = 0.002). Percent change in cotinine concentration differed across groups (reduction = 77% with placebo, 70% with nasal spray, and 48% with patch; p = 0.029). Maternal heart rate decreased in the placebo and nasal spray groups compared with the patch group (p = 0.021). The baseline fetal heart rate decreased in the placebo group throughout the second monitoring session, but increased slightly in the patch and nasal spray groups. The treatment by time interaction was marginally significant (p = 0.052). Daily, cigarette craving decreased more in the patch versus the other groups (p = 0.025). Conclusions. Nicotine patch and nasal spray reduce maternal nicotine exposure compared with smoking and may be effective for smoking cessation.

  • What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?

    by Cheryl A. Oncken, H. R. Kranzler

    Given the substantial health risks of smoking during pregnancy, and the potential of pharmacotherapy to enhance quit rates, a need exists to examine the utility of pharmacotherapy for smoking cessation during pregnancy. We briefly review the first-line medications that are recommended for smoking cessation in nonpregnant adults. Additionally, we review the toxicity of tobacco smoke and the potential risks of pharmacotherapy as evidenced by animal studies. We review in more detail studies conducted in pregnant women, including (a) observational studies, (b) short-term safety and longer term uncontrolled studies, and (c) randomized controlled clinical trials (both effectiveness and efficacy studies). Because the safety and efficacy of pharmacotherapy for smoking cessation during pregnancy have not been established, no definitive recommendations can be made on the topic. Effectiveness trials have shown that nicotine replacement therapy (NRT) enhances smoking cessation during pregnancy, but efficacy trials have not shown an advantage for NRT compared with placebo treatment. Small sample size or poor medication compliance (with either the dose or the duration of treatment) may contribute to lack of efficacy in placebo-controlled NRT trials. However, these trials showed that NRT did not adversely affect birth outcomes and increased birth weight. Based on these findings and the fact that all medications have some risk, psychosocial interventions should be the first treatment option for pregnant smokers. Additional research is needed to determine fully the risks and benefits of the various pharmacotherapies for smoking cessation during pregnancy.


  • Nicotine Gum for Pregnant Smokers

    by Cheryl Oncken, Ellen Dornelas, John Greene, Heather Sankey, Allen Glasmann, Richard Feinn, Henry R. Kranzler

    OBJECTIVE: To estimate the safety and efficacy of treatment with 2-mg nicotine gum for smoking cessation during pregnancy. METHODS: Pregnant women who smoked daily received individualized behavioral counseling and random assignment to a 6-week treatment with 2-mg nicotine gum or placebo followed by a 6-week taper period. Women who did not quit smoking were instructed to reduce the number of cigarettes smoked by substituting with gum. Measures of tobacco exposure were obtained throughout the study. RESULTS: Participants in the nicotine (nequals;100) and placebo (nequals;94) groups were comparable in age, race/ethnicity, and smoking history. Biochemically validated smoking-cessation rates were not significantly higher with nicotine gum compared with placebo (after 6 weeks of treatment: 13% compared with 9.6%, P=.45; at 32–34 weeks of gestation: 18% compared with 14.9%, P=.56). Using a completer analysis, nicotine gum significantly reduced the number of cigarettes smoked per day (nicotine gum: −5.7 [standard deviation (SD)=6.0]; placebo: −3.5 [SD=5.7], P=.035), and cotinine concentration (nicotine gum: −249 ng/mL [SD=397]; placebo: −112 ng/mL [SD=333]; P=.04). Birth weights were significantly greater with nicotine gum compared with placebo (3,287 g [SD=566] and 2,950 g [SD=653], respectively, P<.001). Gestational age was also greater with nicotine-replacement therapy than with placebo (38.9 weeks [SD=1.7] and 38.0 weeks [SD=3.3], respectively; P=.014). CONCLUSION: Although nicotine gum did not increase quit rates, use of nicotine gum increased birth weight and gestational age, two key parameters in predicting neonatal wellbeing. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, www.clinicaltrials.gov , NCT00115687 LEVEL OF EVIDENCE: I